- Home
- LDI vs RZLT Comparison
LDI vs RZLT Comparison
Compare LDI & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LDI | RZLT |
|---|---|---|
| Founded | 2010 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 542.4M | 471.0M |
| IPO Year | 2021 | 2011 |
Fundamental Metrics
Financial Performance| Metric | LDI | RZLT |
|---|---|---|
| Price | $0.60 | $4.11 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 4 | 11 |
| Target Price | $1.13 | ★ $9.80 |
| AVG Volume (30 Days) | ★ 3.0M | 1.6M |
| Earning Date | 11-09-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 23.47 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.77 | N/A |
| Revenue Next Year | $8.43 | $2,214.20 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.48 | $1.07 |
| 52 Week High | $3.24 | $11.46 |
Technical Indicators
Market Signals| Indicator | LDI | RZLT |
|---|---|---|
| Relative Strength Index (RSI) | 47.55 | 49.74 |
| Support Level | $0.57 | $3.58 |
| Resistance Level | $1.19 | $5.43 |
| Average True Range (ATR) | 0.06 | 0.30 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 62.78 | 47.40 |
Price Performance
Historical ComparisonAbout LDI loanDepot Inc.
loanDepot Inc provides nonbank consumer lending solutions for individuals in the United States. It offers personal, residential home, home refinancing, mortgage and home equity loans. It serves customers through distribution channels, including consumer direct centres, retail branches, wholesale centres, and consumer finance and servicing centres in the United States. It competes with commercial banks and financial institutions.
About RZLT Rezolute Inc. (NV)
Rezolute Inc is a late-stage rare disease company focused on developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism. Its main clinical asset, Ersodetug, is a potential treatment for refractory hypoglycemia caused by multiple forms of hyperinsulinism. The company has a single reportable segment, which includes all of its activities as a clinical-stage biopharmaceutical company.